Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Revue De Pneumologie Clinique|November 21, 2008
[Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report]J Mazières, E DansinRevue Des Maladies Respiratoires|November 23, 2007
[Lung cancer in women and pregnancy: towards a hormonal origin?]J Mazières, I Rouquette, L BrouchetRevue Des Maladies Respiratoires|July 9, 2020
[Anti-PD1 immunotherapy followed by tuberculosis infection or reactivation]T Viatgé, J Mazières, S Zahi, et al.Revue Des Maladies Respiratoires|September 27, 2021
[Survival and epidemiological characteristics of women with lung cancer in Reunion]A Kienlen, J Mazières, M André, et al.Revue Des Maladies Respiratoires|October 18, 2016
[Interest of crizotinib in a lung cancer patient with de novo amplification of MET]A Rabeau, I Rouquette, J-M Vantelon, et al.Journal De Radiologie|September 4, 2010
[Thermal ablation: tolerance and efficacy in a population mostly composed of primary lung cancers]F Chamming's, N Lévèque, J Mazières, et al.Oncogene|July 7, 2015
RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibitionE Bousquet, O Calvayrac, J Mazières, et al.ESMO Open|January 28, 2026
Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparisonD Planchard, J Mazières, J M Grouin, et al.Revue Des Maladies Respiratoires|September 15, 2018
[Toxicity of immune checkpoints inhibitors]M Delaunay, P Caron, V Sibaud, et al.Revue Des Maladies Respiratoires|May 25, 2024
[Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK]M Messekher, H François, M G Denis, et al.Pageof 3